Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8504222 | 0.79 | EED (0.45) | EEDHTR2AHTR2CKCNH2 | |
| SCHEMBL957265 | 0.79 | EED (0.45) | EEDHTR2AHTR2CKCNH2 | |
| SCHEMBL2610674 | 0.79 | GABRA1 (0.46) | EEDHTR2AHTR2CKCNH2 | |
| SCHEMBL8058485 | 0.79 | EED (0.45) | EEDHTR2AHTR2CKCNH2 | |
| SCHEMBL17361456 | 0.79 | EED (0.45) | EEDHTR2AHTR2CKCNH2 | |
| SCHEMBL8504101 | 0.77 | TDP1 (0.53) | EED | |
| SCHEMBL20354322 | 0.76 | GABRA1 (0.48) | EEDHTR2AHTR2CKCNH2 | |
| SCHEMBL34462948 | 0.76 | EED (0.43) | EEDHTR2AHTR2CKCNH2 | |
| SCHEMBL3794977 | 0.76 | EED (0.43) | EEDHTR2AHTR2CKCNH2 | |
| SCHEMBL2260036 | 0.76 | EED (0.43) | EEDHTR2AHTR2CKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109069514-B | Antibacterial compound and application thereof | 结核病药物开发全球联盟公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-4148053-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | The Global Alliance for TB Drug Development, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-3426255-B1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2022-11-30 | — | — | EP | disclosed |
| US-10981891-B2 | Antibacterial compounds and uses thereof | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10981891-B2 | Antibacterial compounds and uses thereof | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200039955-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2020-02-06 | — | — | US | disclosed |
| US-20200039955-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2020-02-06 | — | — | US | disclosed |
| US-10508097-B2 | Antibacterial compounds and uses thereof | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2019-12-17 | — | — | US | disclosed |
| US-10508097-B2 | Antibacterial compounds and uses thereof | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2019-12-17 | — | — | US | disclosed |
| US-20190071417-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2019-03-07 | — | — | US | disclosed |
| EP-1027043-B1 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-11-10 | — | — | EP | disclosed |
| CN-1152679-C | Melatonergic agents of benzodioxoles, benzofurans, dihydrobenzofurans and benzodioxanes | ����˹�ж�-����˹˹������˾ | 2004-06-09 | — | — | CN | disclosed |
| EP-1027043-A4 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2002-02-20 | — | — | EP | disclosed |
| EP-1027043-A1 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | Bristol-Myers Squibb Company (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6060506-A | FOR TREATMENT OF SLEEP DISORDERS, CIRCADIAN RHYTHM DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-09 | — | — | US | disclosed |
| CN-1239886-A | Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agent | BRISTOL MYERS SQUIBB CO (US) | 1999-12-29 | — | — | CN | disclosed |
| US-5981571-A | USEFUL AS MELATONERGIC AGENTS IN THE TREATMENT OF SLEEP DISORDERS, SEASONAL DEPRESSION, SHIFTS IN CIRCADIAN CYCLES, MELANCHOLIA, STRESS, APPETITE REGULATION, BENIGN PROSTATIC HYPERPLASIA AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-11-09 | — | — | US | disclosed |
| US-5856529-A | ADJUSTMENT OF NERVOUS SYSTEM, ENDOCRINE FUNCTION; REPRODUCTION, BODY WEIGHT AND METABOLISM | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-01-05 | — | — | US | disclosed |
| WO-1998025606-A1 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
| US-4259338-A | Benzofuranyl-tetrahydropyridines and -piperidines, their acid addition salts and antidepressant preparations thereof | CIBA-GEIGY CORPORATION (US) | 1981-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981891-B2 | Antibacterial compounds and uses thereof | CFTR, SQOR, NQO1 | EED 3711/4885HTR2A 4835/4885HTR2C 4823/4885 |
| US-20200039955-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | CFTR, SQOR, NQO1 | EED 3711/4885HTR2A 4835/4885HTR2C 4823/4885 |
| US-10508097-B2 | Antibacterial compounds and uses thereof | CFTR, SQOR, NQO1 | EED 3711/4885HTR2A 4835/4885HTR2C 4823/4885 |
| US-20190071417-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | CFTR, SQOR, NQO1 | EED 3711/4885HTR2A 4835/4885HTR2C 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.